Tumor microenvironment interacts with tumor cells, establishing an atmosphere to contribute or suppress the tumor development. Among the cells which play a role in the tumor microenvironment, mesenchymal stem cells (MSCs) have been demonstrated to possess the ability to orchestrate the fate of tumor cells, drawing the attention to the field. MSCs have been considered as cells with double-bladed effects, implicating either tumorigenic or anti-tumor activity. On the other side, the promising potential of MSCs in treating human cancer cells has been observed from the clinical studies. Among the beneficial characteristics of MSCs is the natural tumor-trophic migration ability, providing facility for drug delivery and, therefore, targeted treatment to detach tumor and metastatic cells. Moreover, these cells have been the target of engineering approaches, due to their easily implemented traits, in order to obtain the desired expression of anti-angiogenic, anti-proliferative, and pro-apoptotic properties, according to the tumor type. Tumor angiogenesis is the key characteristic of tumor progression and metastasis. Manipulation of angiogenesis has become an attractive approach for cancer therapy since the introduction of the first angiogenesis inhibitor, namely bevacizumab, for metastatic colorectal cancer therapy. This review tries to conclude the approaches, with focus on anti-angiogenesis approach, in implementing the MSCs to combat against tumor cell progression.
Keywords: angiogenesis; cancer therapy; drug delivery; mesenchymal stem cells; tumor microenvironment.
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development.Stem Cells Transl Med. 2017 Dec;6(12):2115-2125. doi: 10.1002/sctm.17-0138. Epub 2017 Oct 26. Stem Cells Transl Med. 2017. PMID: 29072369 Free PMC article. Review.
Extracellular vesicles as regulators of tumor fate: crosstalk among cancer stem cells, tumor cells and mesenchymal stem cells.Stem Cell Investig. 2017 Sep 16;4:75. doi: 10.21037/sci.2017.08.08. eCollection 2017. Stem Cell Investig. 2017. PMID: 29057247 Free PMC article. Review.
Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.Oncotarget. 2017 Jun 27;8(26):42926-42938. doi: 10.18632/oncotarget.17216. Oncotarget. 2017. PMID: 28477013 Free PMC article.
Mesenchymal stem cells promote growth and angiogenesis of tumors in mice.Oncogene. 2013 Sep 12;32(37):4343-54. doi: 10.1038/onc.2012.458. Epub 2012 Oct 22. Oncogene. 2013. PMID: 23085755
Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.Semin Immunol. 2018 Feb;35:69-79. doi: 10.1016/j.smim.2017.12.003. Epub 2017 Dec 27. Semin Immunol. 2018. PMID: 29289420 Free PMC article. Review.
Cited by 3 articles
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.Front Oncol. 2020 Feb 27;10:221. doi: 10.3389/fonc.2020.00221. eCollection 2020. Front Oncol. 2020. PMID: 32175278 Free PMC article. Review.
ERK/MAPK signalling pathway and tumorigenesis.Exp Ther Med. 2020 Mar;19(3):1997-2007. doi: 10.3892/etm.2020.8454. Epub 2020 Jan 15. Exp Ther Med. 2020. PMID: 32104259 Free PMC article. Review.
Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments.Molecules. 2020 Feb 7;25(3):715. doi: 10.3390/molecules25030715. Molecules. 2020. PMID: 32046010 Free PMC article. Review.